{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:47:59Z","timestamp":1787838479064,"version":"build-2784847793"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007613","name":"Majmaah University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007613","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic lymphocytic leukemia (CLL) is an incurable malignancy of B-cells. In this study, bioinformatics analyses were conducted to identify possible pathogenic roles of CK2\u03b1, which is a protein encoded by<jats:italic>CSNK2A1<\/jats:italic>, in the progression and aggressiveness of CLL. Furthermore, various computational tools were used to search for a competent inhibitor of CK2\u03b1 from fungal metabolites that could be proposed for CLL therapy. In CLL patients, high-expression of<jats:italic>CSNK2A1<\/jats:italic>was associated with early need for therapy (n\u2009=\u2009130,<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) and short overall survival (OS; n\u2009=\u2009107,<jats:italic>p<\/jats:italic>\u2009=\u20090.005). Consistently, bioinformatics analyses showed<jats:italic>CSNK2A1<\/jats:italic>to associate with\/play roles in CLL proliferation and survival-dependent pathways. Furthermore, PPI network analysis identified interaction partners of CK2\u03b1 (PPI enrichment<jats:italic>p<\/jats:italic>value\u2009=\u20091\u2009\u00d7\u200910<jats:sup>\u201316<\/jats:sup>) that associated with early need for therapy (n\u2009=\u2009130,<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.003) and have been known to heavily impact on the progression of CLL. These findings constructed a rational for targeting CK2\u03b1 for CLL therapy. Consequently, computational analyses reported 35 fungal metabolites out of 5820 (filtered from 19,967 metabolites) to have lower binding energy (\u0394G: \u2212\u00a010.9 to \u2212\u00a011.7\u00a0kcal\/mol) and better binding affinity (Kd: 9.77\u2009\u00d7\u200910<jats:sup>7<\/jats:sup>\u00a0M<jats:sup>\u22121<\/jats:sup>to 3.77\u2009\u00d7\u200910<jats:sup>8<\/jats:sup>\u00a0M<jats:sup>\u22121<\/jats:sup>) compared with the native ligand (\u0394G: \u2212\u00a010.8, Kd: 8.3\u2009\u00d7\u200910<jats:sup>7<\/jats:sup>\u00a0M\u2212<jats:sup>\u22121<\/jats:sup>). Furthermore, molecular dynamics simulation study established that Butyl Xanalterate-CK2\u03b1 complex continuously remained stable throughout the simulation time (100\u00a0ns). Moreover, Butyl Xanalterate interacted with most of the catalytic residues, where complex was stabilized by more than 65% hydrogen bond interactions, and a significant hydrophobic interaction with residue Phe113. Here, high-expression of<jats:italic>CSNK2A1<\/jats:italic>was implicated in the progression and poor prognosis of CLL, making it a potential therapeutic target in the disease. Butyl Xanalterate showed stable and strong interactions with CK2\u03b1, thus we propose it as a competitive inhibitor of CK2\u03b1 for CLL therapy.<\/jats:p>","DOI":"10.1038\/s41598-022-21546-0","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T10:03:36Z","timestamp":1666346616000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["In silico investigations identified Butyl Xanalterate to competently target CK2\u03b1 (CSNK2A1) for therapy of chronic lymphocytic leukemia"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2242-5638","authenticated-orcid":false,"given":"Suliman A.","family":"Alsagaby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3033-4226","authenticated-orcid":false,"given":"Danish","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7697-9572","authenticated-orcid":false,"given":"Iqrar","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0920-1266","authenticated-orcid":false,"given":"Harun","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabir Ahmad","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahya Awaji","family":"Madkhali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8762-4999","authenticated-orcid":false,"given":"Atif Abdulwahab A.","family":"Oyouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef M.","family":"Hawsawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad A.","family":"Alhumaydhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bader","family":"Alshehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"Alturaiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bader","family":"Alanazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manzoor Ahmad","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Al Abdulmonem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"key":"21546_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12938-021-00973-6","volume":"21","author":"Y Yao","year":"2022","unstructured":"Yao, Y., Lin, X., Li, F., Jin, J. & Wang, H. The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: Analysis based on the global burden of disease study 2019. Biomed. Eng. Online 21, 1\u201322 (2022).","journal-title":"Biomed. Eng. Online"},{"key":"21546_CR2","doi-asserted-by":"publisher","first-page":"a035220","DOI":"10.1101\/cshperspect.a035220","volume":"11","author":"N Chiorazzi","year":"2021","unstructured":"Chiorazzi, N., Chen, S.-S. & Rai, K. R. Chronic lymphocytic leukemia. Cold Spring Harb. Perspect. Med. 11, a035220 (2021).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"21546_CR3","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.clml.2016.08.008","volume":"16","author":"SA Alsagaby","year":"2016","unstructured":"Alsagaby, S. A., Brennan, P. & Pepper, C. Key molecular drivers of chronic lymphocytic leukemia. Clin. Lymphoma Myeloma Leuk. 16, 593\u2013606 (2016).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"21546_CR4","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","volume":"343","author":"H D\u00f6hner","year":"2000","unstructured":"D\u00f6hner, H. et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 343, 1910\u20131916 (2000).","journal-title":"N. Engl. J. Med."},{"key":"21546_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejbt.2021.04.006","volume":"52","author":"SA Alsagaby","year":"2021","unstructured":"Alsagaby, S. A. et al. Proteomics-based identification of cancer-associated proteins in chronic lymphocytic leukaemia. Electron. J. Biotechnol. 52, 1\u201312 (2021).","journal-title":"Electron. J. Biotechnol."},{"key":"21546_CR6","doi-asserted-by":"publisher","first-page":"317","DOI":"10.15537\/smj.2019.4.23598","volume":"40","author":"SA Alsagaby","year":"2019","unstructured":"Alsagaby, S. A. & Alhumaydhi, F. A. Proteomics insights into the pathology and prognosis of chronic lymphocytic leukemia. Saudi Med. J. 40, 317\u2013327 (2019).","journal-title":"Saudi Med. J."},{"key":"21546_CR7","doi-asserted-by":"publisher","first-page":"5051","DOI":"10.1021\/pr5002803","volume":"13","author":"SA Alsagaby","year":"2014","unstructured":"Alsagaby, S. A. et al. Proteomics-based strategies to identify proteins relevant to chronic lymphocytic leukemia. J. Proteome Res. 13, 5051\u20135062 (2014).","journal-title":"J. Proteome Res."},{"key":"21546_CR8","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1049\/iet-nbt.2015.0001","volume":"9","author":"K Govindaraju","year":"2015","unstructured":"Govindaraju, K., Krishnamoorthy, K., Alsagaby, S. A., Singaravelu, G. & Premanathan, M. Green synthesis of silver nanoparticles for selective toxicity towards cancer cells. IET Nanobiotechnol. 9, 325\u2013330 (2015).","journal-title":"IET Nanobiotechnol."},{"key":"21546_CR9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.4081\/oncol.2019.435","volume":"13","author":"SA Alsagaby","year":"2019","unstructured":"Alsagaby, S. A. Omics-based insights into therapy failure of pediatric B-lineage acute lymphoblastic leukemia. Oncol. Rev. 13, 149\u2013155 (2019).","journal-title":"Oncol. Rev."},{"key":"21546_CR10","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1080\/21691401.2019.1614017","volume":"47","author":"Y Ke","year":"2019","unstructured":"Ke, Y. et al. Photosynthesized gold nanoparticles from Catharanthus roseus induces caspase-mediated apoptosis in cervical cancer cells (HeLa). Artif. Cells Nanomed. Biotechnol. 47, 1938\u20131946 (2019).","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"21546_CR11","doi-asserted-by":"publisher","first-page":"7901","DOI":"10.2147\/IJN.S261636","volume":"15","author":"SA Alsagaby","year":"2020","unstructured":"Alsagaby, S. A. et al. Transcriptomics-based characterization of the toxicity of zno nanoparticles against chronic myeloid leukemia cells. Int. J. Nanomed. 15, 7901 (2020).","journal-title":"Int. J. Nanomed."},{"key":"21546_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/6633386","volume":"2021","author":"SA Alsagaby","year":"2021","unstructured":"Alsagaby, S. A. Molecular insights into the potential of extracellular vesicles released from mesenchymal stem cells and other cells in the therapy of hematologic malignancies. Stem Cells Int. 2021, 1\u201315 (2021).","journal-title":"Stem Cells Int."},{"key":"21546_CR13","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.2147\/IJN.S355408","volume":"17","author":"SA Alsagaby","year":"2022","unstructured":"Alsagaby, S. A. Transcriptomics-based investigation of molecular mechanisms underlying apoptosis induced by ZnO nanoparticles in human diffuse large B-cell lymphoma. Int. J. Nanomed. 17, 2261\u20132281 (2022).","journal-title":"Int. J. Nanomed."},{"key":"21546_CR14","first-page":"519","volume":"12","author":"S Bijani","year":"2022","unstructured":"Bijani, S. et al. Green synthesis and anticancer potential of 1,4-dihydropyridines-based triazole derivatives: In silico and in vitro study. Life (Basel) 12, 519 (2022).","journal-title":"Life (Basel)"},{"key":"21546_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/JBT.23146","author":"VD Seshadri","year":"2022","unstructured":"Seshadri, V. D. et al. Zingiberene exerts chemopreventive activity against 7,12-dimethylbenz(a)anthracene-induced breast cancer in Sprague-Dawley rats. J. Biochem. Mol. Toxicol. https:\/\/doi.org\/10.1002\/JBT.23146 (2022).","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"21546_CR16","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s00277-017-2982-1","volume":"96","author":"C Shustik","year":"2017","unstructured":"Shustik, C. et al. Advances in the treatment of relapsed\/refractory chronic lymphocytic leukemia. Ann. Hematol. 96, 1185\u20131196 (2017).","journal-title":"Ann. Hematol."},{"key":"21546_CR17","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1056\/NEJMra1908213","volume":"383","author":"JA Burger","year":"2020","unstructured":"Burger, J. A. Treatment of chronic lymphocytic leukemia. N. Engl. J. Med. 383, 460\u2013473 (2020).","journal-title":"N. Engl. J. Med."},{"key":"21546_CR18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1042\/BJ20140178","volume":"460","author":"A Venerando","year":"2014","unstructured":"Venerando, A., Ruzzene, M. & Pinna, L. A. Casein kinase: The triple meaning of a misnomer. Biochem. J. 460, 141\u2013156 (2014).","journal-title":"Biochem. J."},{"key":"21546_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2174\/1568009043481687","volume":"4","author":"GM Unger","year":"2004","unstructured":"Unger, G. M., Davis, A. T., Slaton, J. W. & Ahmed, K. Protein kinase CK2 as regulator of cell survival: Implications for cancer therapy. Curr. Cancer Drug Targets 4, 77\u201384 (2004).","journal-title":"Curr. Cancer Drug Targets"},{"key":"21546_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/leu.2017.301","volume":"32","author":"F Buontempo","year":"2018","unstructured":"Buontempo, F. et al. Therapeutic targeting of CK2 in acute and chronic leukemias. Leukemia 32, 1\u201310 (2018).","journal-title":"Leukemia"},{"key":"21546_CR21","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1182\/blood-2009-10-248054","volume":"116","author":"M Shehata","year":"2010","unstructured":"Shehata, M. et al. Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K\/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia. Blood 116, 2513\u20132521 (2010).","journal-title":"Blood"},{"key":"21546_CR22","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.3390\/ijms22073716","volume":"22","author":"Z Spinello","year":"2021","unstructured":"Spinello, Z. et al. Targeting protein kinases in blood cancer: Focusing on CK1\u03b1 and CK2. Int. J. Mol. Sci. 22, 3716 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"21546_CR23","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1182\/blood.V114.22.803.803","volume":"114","author":"LR Martins","year":"2009","unstructured":"Martins, L. R., L\u00facio, P., Gameiro, P., Silva, M. G. & Barata, J. T. Targeting CK2 overexpression as a novel therapeutic tool in chronic lymphocytic leukemia. Blood 114, 803 (2009).","journal-title":"Blood"},{"key":"21546_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11010-011-0947-6","volume":"356","author":"LR Martins","year":"2011","unstructured":"Martins, L. R. et al. On CK2 regulation of chronic lymphocytic leukemia cell viability. Mol. Cell Biochem. 356, 51\u201355 (2011).","journal-title":"Mol. Cell Biochem."},{"key":"21546_CR25","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1182\/blood.V128.22.2050.2050","volume":"128","author":"C Wu","year":"2016","unstructured":"Wu, C. et al. Inhibition of casein kinase 2 impairs Wnt signaling and cell survival in chronic lymphocytic leukemia. Blood 128, 2050 (2016).","journal-title":"Blood"},{"key":"21546_CR26","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3389\/fphar.2015.00070","volume":"6","author":"HJ Chon","year":"2015","unstructured":"Chon, H. J., Bae, K. J., Lee, Y. & Kim, J. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies. Front. Pharmacol. 6, 70 (2015).","journal-title":"Front. Pharmacol."},{"key":"21546_CR27","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/leu.2013.232","volume":"28","author":"LR Martins","year":"2014","unstructured":"Martins, L. R. et al. Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia. Leukemia 28, 179\u2013182 (2014).","journal-title":"Leukemia"},{"key":"21546_CR28","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41392-021-00567-7","volume":"6","author":"C Borgo","year":"2021","unstructured":"Borgo, C., D\u2019Amore, C., Sarno, S., Salvi, M. & Ruzzene, M. Protein kinase CK2: A potential therapeutic target for diverse human diseases. Signal Transduct. Target Ther. 6, 183 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"21546_CR29","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s13402-020-00566-w","volume":"43","author":"C D\u2019Amore","year":"2020","unstructured":"D\u2019Amore, C., Borgo, C., Sarno, S. & Salvi, M. Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy\u2013potential clinical relevance. Cell. Oncol. 43, 1003\u20131016 (2020).","journal-title":"Cell. Oncol."},{"key":"21546_CR30","doi-asserted-by":"publisher","first-page":"103520","DOI":"10.1016\/j.bioorg.2019.103520","volume":"95","author":"S Oramas-Royo","year":"2020","unstructured":"Oramas-Royo, S. et al. Design, synthesis and biological evaluation of new embelin derivatives as CK2 inhibitors. Bioorg. Chem. 95, 103520 (2020).","journal-title":"Bioorg. Chem."},{"key":"21546_CR31","doi-asserted-by":"publisher","first-page":"12786","DOI":"10.1021\/acs.jmedchem.0c01173","volume":"63","author":"P Brear","year":"2020","unstructured":"Brear, P., Ball, D., Stott, K., D\u2019Arcy, S. & Hyv\u00f6nen, M. Proposed allosteric inhibitors bind to the ATP site of CK2\u03b1. J. Med. Chem. 63, 12786\u201312798 (2020).","journal-title":"J. Med. Chem."},{"key":"21546_CR32","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1021\/acs.chemrev.0c00383","volume":"121","author":"RA Ward","year":"2020","unstructured":"Ward, R. A. et al. Challenges and opportunities in cancer drug resistance. Chem. Rev. 121, 3297\u20133351 (2020).","journal-title":"Chem. Rev."},{"key":"21546_CR33","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41568-020-00302-4","volume":"20","author":"J-C Marine","year":"2020","unstructured":"Marine, J.-C., Dawson, S.-J. & Dawson, M. A. Non-genetic mechanisms of therapeutic resistance in cancer. Nat. Rev. Cancer 20, 743\u2013756 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"21546_CR34","first-page":"1","volume":"4","author":"J Ahmad","year":"2013","unstructured":"Ahmad, J., Khan, I., Khan, S. & Iqba, D. Evaluation of antioxidant and antimicrobial activity of Ficus carica Leaves: an in vitro approach. J. Plant Pathol. Microbiol. 4, 1\u20134 (2013).","journal-title":"J. Plant Pathol. Microbiol."},{"key":"21546_CR35","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.msec.2017.03.282","volume":"78","author":"N Ahmad","year":"2017","unstructured":"Ahmad, N. et al. Biosynthesis and characterization of gold nanoparticles: Kinetics, in vitro and in vivo study. Mater. Sci. Eng. C 78, 553\u2013564 (2017).","journal-title":"Mater. Sci. Eng. C"},{"key":"21546_CR36","doi-asserted-by":"publisher","first-page":"117756","DOI":"10.1016\/j.lfs.2020.117756","volume":"254","author":"P Ahmad","year":"2020","unstructured":"Ahmad, P., Alvi, S. S., Iqbal, D. & Khan, M. S. Insights into pharmacological mechanisms of polydatin in targeting risk factors-mediated atherosclerosis. Life Sci. 254, 117756 (2020).","journal-title":"Life Sci."},{"key":"21546_CR37","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.sajb.2013.06.024","volume":"88","author":"F Akhter","year":"2013","unstructured":"Akhter, F. et al. Antioxidant, \u03b1-amylase inhibitory and oxidative DNA damage protective property of Boerhaavia diffusa (Linn.) root. S. Afr. J. Bot. 88, 265\u2013272 (2013).","journal-title":"S. Afr. J. Bot."},{"key":"21546_CR38","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.15419\/bmrat.v6i7.556","volume":"6","author":"F Akhter","year":"2019","unstructured":"Akhter, F. et al. Therapeutic efficacy of Boerhaavia diffusa (Linn.) root methanolic extract in attenuating streptozotocin-induced diabetes, diabetes-linked hyperlipidemia and oxidative-stress in rats. Biomed. Res. Ther. 6, 3293\u20133306 (2019).","journal-title":"Biomed. Res. Ther."},{"key":"21546_CR39","first-page":"1","volume-title":"Natural Bio-active Compounds","author":"SS Alvi","year":"2019","unstructured":"Alvi, S. S., Ahmad, P., Ishrat, M., Iqbal, D. & Khan, M. S. Secondary metabolites from rosemary (Rosmarinus officinalis L.): Structure, biochemistry and therapeutic implications against neurodegenerative diseases. In Natural Bio-active Compounds (eds Swamy, M. K. & Akhtar, M. S.) 1\u201324 (Springer, 2019)."},{"key":"21546_CR40","doi-asserted-by":"publisher","first-page":"46","DOI":"10.9734\/jpri\/2021\/v33i1131243","volume":"2021","author":"D Iqbal","year":"2021","unstructured":"Iqbal, D., Dukhyil, A. B. & Khan, M. S. Geno-protective, free radical scavenging and antimicrobial potential of Hyptis suaveolens Methanolic fraction: An in-vitro study. J. Pharm. Res. Int 2021, 46\u201357 (2021).","journal-title":"J. Pharm. Res. Int"},{"key":"21546_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7603\/s40730-016-0033-5","volume":"3","author":"D Iqbal","year":"2016","unstructured":"Iqbal, D., Khan, M. S., Khan, A. & Ahmad, S. Extenuating the role of Ficus virens Ait and its novel bioactive compound on antioxidant defense system and oxidative damage in cigarette smoke exposed rats. Biomed. Res. Ther. 3, 1\u201310 (2016).","journal-title":"Biomed. Res. Ther."},{"key":"21546_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-015-0013-6","volume":"14","author":"D Iqbal","year":"2015","unstructured":"Iqbal, D. et al. Bioactivity guided fractionation and hypolipidemic property of a novel HMG-CoA reductase inhibitor from Ficus virens Ait. Lipids Health Dis. 14, 1\u201315 (2015).","journal-title":"Lipids Health Dis."},{"key":"21546_CR43","first-page":"1089","volume":"16","author":"D Iqbal","year":"2017","unstructured":"Iqbal, D., Khan, A., Ansari, I. A. & Khan, M. S. Investigating the role of novel bioactive compound from ficus virens ait on cigarette smoke induced oxidative stress and hyperlipidemia in rats. Iran. J. Pharm. Res. 16, 1089 (2017).","journal-title":"Iran. J. Pharm. Res."},{"key":"21546_CR44","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/ptr.5077","volume":"28","author":"D Iqbal","year":"2014","unstructured":"Iqbal, D., Khan, M. S., Khan, M. S., Ahmad, S. & Srivastava, A. K. An in vitro and molecular informatics study to evaluate the antioxidative and \u03b2-hydroxy-\u03b2-methylglutaryl-CoA reductase inhibitory property of Ficus virens Ait. Phytother. Res. 28, 899\u2013908 (2014).","journal-title":"Phytother. Res."},{"key":"21546_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/762620","volume":"2014","author":"D Iqbal","year":"2014","unstructured":"Iqbal, D. et al. In vitro screening for \u03b2-hydroxy-\u03b2-methylglutaryl-coa reductase inhibitory and antioxidant activity of sequentially extracted fractions of Ficus palmata Forsk. Biomed. Res. Int. 2014, 1\u201310 (2014).","journal-title":"Biomed. Res. Int."},{"key":"21546_CR46","doi-asserted-by":"publisher","first-page":"937","DOI":"10.3390\/ph14090937","volume":"14","author":"D Iqbal","year":"2021","unstructured":"Iqbal, D. et al. High-throughput screening and molecular dynamics simulation of natural product-like compounds against Alzheimer\u2019s disease through multitarget approach. Pharmaceuticals 14, 937 (2021).","journal-title":"Pharmaceuticals"},{"key":"21546_CR47","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.lfs.2018.08.046","volume":"209","author":"A Khatoon","year":"2018","unstructured":"Khatoon, A. et al. Silver nanoparticles from leaf extract of Mentha piperita: Eco-friendly synthesis and effect on acetylcholinesterase activity. Life Sci. 209, 430\u2013434 (2018).","journal-title":"Life Sci."},{"key":"21546_CR48","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.eujim.2016.01.004","volume":"8","author":"M Khushtar","year":"2016","unstructured":"Khushtar, M. et al. Amelioration of gastric ulcers using a hydro-alcoholic extract of Triphala in indomethacin-induced Wistar rats. Eur. J. Integr. Med. 8, 546\u2013551 (2016).","journal-title":"Eur. J. Integr. Med."},{"key":"21546_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-00114-z","author":"AG Atanasov","year":"2021","unstructured":"Atanasov, A. G. et al. Natural products in drug discovery: Advances and opportunities. Nat. Rev. Drug Discov. https:\/\/doi.org\/10.1038\/s41573-020-00114-z (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"21546_CR50","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/nyas.13387","volume":"1401","author":"R Yuan","year":"2017","unstructured":"Yuan, R. et al. Natural products to prevent drug resistance in cancer chemotherapy: A review. Ann. N. Y. Acad. Sci. 1401, 19\u201327 (2017).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"21546_CR51","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2174\/1573407214666180622104720","volume":"15","author":"S Saxena","year":"2019","unstructured":"Saxena, S., Chhibber, M. & Singh, I. P. Fungal bioactive compounds in pharmaceutical research and development. Cur.r Bioact. Compd. 15, 211\u2013231 (2019).","journal-title":"Cur.r Bioact. Compd."},{"key":"21546_CR52","unstructured":"Progress in the Chemistry of Organic Natural Products|Book series home. https:\/\/www.springer.com\/series\/10169."},{"key":"21546_CR53","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1021\/np400762k","volume":"76","author":"Y Xu","year":"2013","unstructured":"Xu, Y., Espinosa-Artiles, P., Liu, M. X., Arnold, A. E. & Gunatilaka, A. A. L. Secoemestrin D, a cytotoxic epitetrathiodioxopiperizine, and emericellenes A-E, five sesterterpenoids from Emericella sp. AST0036, a fungal endophyte of Astragalus lentiginosus 1. J. Nat. Prod. 76, 2330\u20132336 (2013).","journal-title":"J. Nat. Prod."},{"key":"21546_CR54","doi-asserted-by":"publisher","first-page":"328","DOI":"10.15537\/smj.2019.4.23380","volume":"40","author":"SA Alsagaby","year":"2019","unstructured":"Alsagaby, S. A. Transcriptomics-based validation of the relatedness of heterogeneous nuclear ribonucleoproteins to chronic lymphocytic leukemia as potential biomarkers of the disease aggressiveness. Saudi Med. J. 40, 328\u2013338 (2019).","journal-title":"Saudi Med. J."},{"key":"21546_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-69033-8","volume":"10","author":"FA Alzahrani","year":"2020","unstructured":"Alzahrani, F. A. et al. Investigating the pathogenic SNPs in BLM helicase and their biological consequences by computational approach. Sci. Rep. 10, 12377 (2020).","journal-title":"Sci. Rep."},{"key":"21546_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/5515692","volume":"2021","author":"MM Fareed","year":"2021","unstructured":"Fareed, M. M. et al. In silico drug screening analysis against the overexpression of PGAM1 gene in different cancer treatments. Biomed. Res. Int. 2021, 1\u20137 (2021).","journal-title":"Biomed. Res. Int."},{"key":"21546_CR57","doi-asserted-by":"publisher","first-page":"7872","DOI":"10.1039\/D1RA09339H","volume":"12","author":"F Anjum","year":"2022","unstructured":"Anjum, F. et al. Bioactive phytoconstituents as potent inhibitors of casein kinase-2: Dual implications in cancer and COVID-19 therapeutics. RSC Adv. 12, 7872\u20137882 (2022).","journal-title":"RSC Adv."},{"key":"21546_CR58","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1039\/D2MD00053A","volume":"13","author":"A Shamsi","year":"2022","unstructured":"Shamsi, A. et al. Inhibition of MARK4 by serotonin as an attractive therapeutic approach to combat Alzheimer\u2019s disease and neuroinflammation. RSC Med. Chem. 13, 737\u2013745 (2022).","journal-title":"RSC Med. Chem."},{"key":"21546_CR59","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.3390\/molecules27103060","volume":"27","author":"C Yang","year":"2022","unstructured":"Yang, C. et al. Bioactive phytoconstituents as potent inhibitors of tyrosine-protein kinase yes (YES1): Implications in anticancer therapeutics. Molecules 27, 3060 (2022).","journal-title":"Molecules"},{"key":"21546_CR60","doi-asserted-by":"publisher","first-page":"118581","DOI":"10.1016\/j.molliq.2022.118581","volume":"350","author":"S Anwar","year":"2022","unstructured":"Anwar, S. et al. Implications of tempol in pyruvate dehydrogenase kinase 3 targeted anticancer therapeutics: Computational, spectroscopic, and calorimetric studies. J. Mol. Liq. 350, 118581 (2022).","journal-title":"J. Mol. Liq."},{"key":"21546_CR61","doi-asserted-by":"publisher","first-page":"118928","DOI":"10.1016\/j.molliq.2022.118928","volume":"355","author":"S Anwar","year":"2022","unstructured":"Anwar, S. et al. Inhibition of PDK3 by artemisinin, a repurposed antimalarial drug in cancer therapy. J Mol Liq 355, 118928 (2022).","journal-title":"J Mol Liq"},{"key":"21546_CR62","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/leu.2011.125","volume":"25","author":"T Herold","year":"2011","unstructured":"Herold, T. et al. An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia. Leukemia 25, 1639\u20131645 (2011).","journal-title":"Leukemia"},{"key":"21546_CR63","first-page":"2639","volume":"120","author":"H-Y Chuang","year":"2012","unstructured":"Chuang, H.-Y. et al. Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression. Blood J. Am. Soc. Hematol. 120, 2639\u20132649 (2012).","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"21546_CR64","doi-asserted-by":"publisher","first-page":"W307","DOI":"10.1093\/nar\/gkr378","volume":"39","author":"J Reimand","year":"2011","unstructured":"Reimand, J., Arak, T. & Vilo, J. g: Profiler\u2014A web server for functional interpretation of gene lists (2011 update). Nucleic Acids Res. 39, W307\u2013W315 (2011).","journal-title":"Nucleic Acids Res."},{"key":"21546_CR65","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"M Ashburner","year":"2000","unstructured":"Ashburner, M. et al. Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 25, 25\u201329 (2000).","journal-title":"Nat. Genet."},{"key":"21546_CR66","doi-asserted-by":"publisher","first-page":"D325","DOI":"10.1093\/nar\/gkaa1113","volume":"49","author":"S Carbon","year":"2021","unstructured":"Carbon, S. et al. The Gene Ontology resource: Enriching a GOld mine. Nucleic Acids Res. 49, D325\u2013D334 (2021).","journal-title":"Nucleic Acids Res."},{"key":"21546_CR67","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"key":"21546_CR68","doi-asserted-by":"publisher","first-page":"D687","DOI":"10.1093\/nar\/gkab1028","volume":"50","author":"M Gillespie","year":"2022","unstructured":"Gillespie, M. et al. The reactome pathway knowledgebase 2022. Nucleic Acids Res. 50, D687\u2013D692 (2022).","journal-title":"Nucleic Acids Res."},{"key":"21546_CR69","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1371\/journal.pbio.0060184","volume":"6","author":"AR Pico","year":"2008","unstructured":"Pico, A. R. et al. WikiPathways: Pathway editing for the people. PLoS Biol. 6, 1403\u20131407 (2008).","journal-title":"PLoS Biol."},{"key":"21546_CR70","doi-asserted-by":"publisher","first-page":"D607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"Szklarczyk, D. et al. STRING v11: Protein\u2013protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47, D607\u2013D613 (2019).","journal-title":"Nucleic Acids Res."},{"key":"21546_CR71","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon, P. et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498\u20132504 (2003).","journal-title":"Genome Res."},{"key":"21546_CR72","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina, A., Michielin, O. & Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 7, 42717 (2017).","journal-title":"Sci. Rep."},{"key":"21546_CR73","unstructured":"ADMETlab 2.0. https:\/\/admetmesh.scbdd.com\/."},{"key":"21546_CR74","doi-asserted-by":"publisher","first-page":"W5","DOI":"10.1093\/nar\/gkab255","volume":"49","author":"G Xiong","year":"2021","unstructured":"Xiong, G. et al. ADMETlab 2.0: An integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res. 49, W5\u2013W14 (2021).","journal-title":"Nucleic Acids Res."},{"key":"21546_CR75","unstructured":"ProTox-II - Prediction of TOXicity of chemicals. https:\/\/tox-new.charite.de\/protox_II\/."},{"key":"21546_CR76","doi-asserted-by":"publisher","first-page":"W257","DOI":"10.1093\/nar\/gky318","volume":"46","author":"P Banerjee","year":"2018","unstructured":"Banerjee, P., Eckert, O. A., Schrey, A. K. & Preissner, R. ProTox-II: A webserver for the prediction of toxicity of chemicals. Nucleic Acids Res. 46, W257\u2013W263 (2018).","journal-title":"Nucleic Acids Res."},{"key":"21546_CR77","doi-asserted-by":"publisher","first-page":"103345","DOI":"10.1016\/j.arabjc.2021.103345","volume":"14","author":"M Prasathkumar","year":"2021","unstructured":"Prasathkumar, M. et al. Phytochemical screening and in vitro antibacterial, antioxidant, anti-inflammatory, anti-diabetic, and wound healing attributes of Senna auriculata (L.) Roxb. leaves. Arab. J. Chem. 14, 103345 (2021).","journal-title":"Arab. J. Chem."},{"key":"21546_CR78","doi-asserted-by":"publisher","first-page":"8478","DOI":"10.1021\/bi2008382","volume":"50","author":"R Battistutta","year":"2011","unstructured":"Battistutta, R. et al. Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer. Biochemistry 50, 8478\u20138488 (2011).","journal-title":"Biochemistry"},{"key":"21546_CR79","doi-asserted-by":"publisher","first-page":"D437","DOI":"10.1093\/nar\/gkaa1038","volume":"49","author":"SK Burley","year":"2021","unstructured":"Burley, S. K. et al. RCSB Protein Data Bank: Powerful new tools for exploring 3D structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering and energy sciences. Nucleic Acids Res. 49, D437\u2013D451 (2021).","journal-title":"Nucleic Acids Res."},{"key":"21546_CR80","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/978-1-4939-2269-7_19","volume-title":"Chemical Biology","author":"S Dallakyan","year":"2015","unstructured":"Dallakyan, S. & Olson, A. J. Small-molecule library screening by docking with PyRx. In Chemical Biology (eds Hempel, J. E. et al.) 243\u2013250 (Springer, 2015)."},{"key":"21546_CR81","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2009","unstructured":"Trott, O. & Olson, A. J. Software news and update AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455\u2013461 (2009).","journal-title":"J. Comput. Chem."},{"key":"21546_CR82","unstructured":"BIOVIA Discovery Studio - BIOVIA - Dassault Syst\u00e8mes\u00ae. https:\/\/www.3ds.com\/products-services\/biovia\/products\/molecular-modeling-simulation\/biovia-discovery-studio\/."},{"key":"21546_CR83","first-page":"1","volume":"11","author":"JV Akshatha","year":"2021","unstructured":"Akshatha, J. V., SantoshKumar, H. S., Prakash, H. S. & Nalini, M. S. In silico docking studies of \u03b1-amylase inhibitors from the anti-diabetic plant Leucas ciliata Benth and an endophyte, Streptomyces longisporoflavus. 3Biotech 11, 1\u201316 (2021).","journal-title":"3Biotech"},{"key":"21546_CR84","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2174\/1386207323666201204125524","volume":"25","author":"H Patel","year":"2022","unstructured":"Patel, H. et al. Investigating the impact of different acrylamide (electrophilic warhead) on Osimertinib\u2019s pharmacological Spectrum by molecular mechanic and quantum mechanic approach. Comb. Chem. High Throughput Screen 25, 149\u2013166 (2022).","journal-title":"Comb. Chem. High Throughput Screen"},{"key":"21546_CR85","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/10799893.2018.1557207","volume":"38","author":"H Patel","year":"2018","unstructured":"Patel, H. et al. Design and synthesis of novel 2, 4-disubstituted aminopyrimidines: Reversible non-covalent T790M EGFR inhibitors. J. Recept. Signal Transduct. 38, 393\u2013412 (2018).","journal-title":"J. Recept. Signal Transduct."},{"key":"21546_CR86","doi-asserted-by":"publisher","first-page":"105234","DOI":"10.1016\/j.bioorg.2021.105234","volume":"115","author":"R Pawara","year":"2021","unstructured":"Pawara, R. et al. Novel, selective acrylamide linked quinazolines for the treatment of double mutant EGFR-L858R\/T790M Non-Small-Cell lung cancer (NSCLC). Bioorg. Chem. 115, 105234 (2021).","journal-title":"Bioorg. Chem."},{"key":"21546_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40203-021-00113-x","volume":"9","author":"R Pawara","year":"2021","unstructured":"Pawara, R., Ahmad, I., Surana, S. & Patel, H. Computational identification of 2, 4-disubstituted amino-pyrimidines as L858R\/T790M-EGFR double mutant inhibitors using pharmacophore mapping, molecular docking, binding free energy calculation, DFT study and molecular dynamic simulation. In Silico Pharmacol. 9, 1\u201322 (2021).","journal-title":"In Silico Pharmacol."},{"key":"21546_CR88","doi-asserted-by":"publisher","first-page":"11225","DOI":"10.1021\/ja9621760","volume":"118","author":"WL Jorgensen","year":"1996","unstructured":"Jorgensen, W. L., Maxwell, D. S. & Tirado-Rives, J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J. Am. Chem. Soc. 118, 11225\u201311236 (1996).","journal-title":"J. Am. Chem. Soc."},{"key":"21546_CR89","doi-asserted-by":"publisher","first-page":"7991","DOI":"10.1080\/07391102.2021.1905553","volume":"40","author":"I Ahmad","year":"2021","unstructured":"Ahmad, I., Kumar, D. & Patel, H. Computational investigation of phytochemicals from Withania somnifera (Indian ginseng\/ashwagandha) as plausible inhibitors of GluN2B-containing NMDA receptors. J. Biomol. Struct. Dyn. 40, 7991\u20138003 (2021).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"21546_CR90","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1080\/0026897021000044025","volume":"101","author":"G Kalibaeva","year":"2003","unstructured":"Kalibaeva, G., Ferrario, M. & Ciccotti, G. Constant pressure-constant temperature molecular dynamics: A correct constrained NPT ensemble using the molecular virial. Mol. Phys. 101, 765\u2013778 (2003).","journal-title":"Mol. Phys."},{"key":"21546_CR91","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1103\/PhysRevE.50.3234","volume":"50","author":"GJ Martyna","year":"1994","unstructured":"Martyna, G. J. Remarks on \u2018\u201cConstant-temperature molecular dynamics with momentum conservation\u201d\u2019. Phys. Rev. E 50, 3234 (1994).","journal-title":"Phys. Rev. E"},{"key":"21546_CR92","doi-asserted-by":"publisher","first-page":"10693","DOI":"10.3390\/ijms221910693","volume":"22","author":"R Zrieq","year":"2021","unstructured":"Zrieq, R. et al. Tomatidine and Patchouli alcohol as inhibitors of SARS-CoV-2 enzymes (3CLpro, PLpro and NSP15) by molecular docking and molecular dynamics simulations. Int. J. Mol. Sci. 22, 10693 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"21546_CR93","doi-asserted-by":"publisher","first-page":"W147","DOI":"10.1093\/nar\/gkw419","volume":"44","author":"S Babicki","year":"2016","unstructured":"Babicki, S. et al. Heatmapper: Web-enabled heat mapping for all. Nucleic Acids Res. 44, W147\u2013W153 (2016).","journal-title":"Nucleic Acids Res."},{"key":"21546_CR94","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/cncr.31931","volume":"125","author":"S Sharma","year":"2019","unstructured":"Sharma, S. & Rai, K. R. Chronic lymphocytic leukemia (CLL) treatment: So many choices, such great options. Cancer 125, 1432\u20131440 (2019).","journal-title":"Cancer"},{"key":"21546_CR95","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1182\/blood-2010-04-277947","volume":"116","author":"LR Martins","year":"2010","unstructured":"Martins, L. R. et al. Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia. Blood 116, 2724\u20132731 (2010).","journal-title":"Blood"},{"key":"21546_CR96","doi-asserted-by":"publisher","first-page":"42571","DOI":"10.18632\/oncotarget.17246","volume":"8","author":"M Russo","year":"2017","unstructured":"Russo, M. et al. CK2 and PI3K are direct molecular targets of quercetin in chronic lymphocytic leukaemia. Oncotarget 8, 42571 (2017).","journal-title":"Oncotarget"},{"key":"21546_CR97","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-06-1602","volume":"13","author":"JS Kim","year":"2007","unstructured":"Kim, J. S. et al. Protein kinase CK2\u03b1 as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia. Clin. Cancer Res. 13, 1019\u20131028 (2007).","journal-title":"Clin. Cancer Res."},{"key":"21546_CR98","doi-asserted-by":"publisher","first-page":"34800","DOI":"10.18632\/oncotarget.5470","volume":"6","author":"H-X Zhang","year":"2015","unstructured":"Zhang, H.-X. et al. Protein kinase CK2\u03b1 catalytic subunit is overexpressed and serves as an unfavorable prognostic marker in primary hepatocellular carcinoma. Oncotarget 6, 34800 (2015).","journal-title":"Oncotarget"},{"key":"21546_CR99","doi-asserted-by":"publisher","first-page":"e0174037","DOI":"10.1371\/journal.pone.0174037","volume":"12","author":"Z Ma","year":"2017","unstructured":"Ma, Z., Wang, X., He, J., Xia, J. & Li, Y. Increased expression of protein kinase CK2\u03b1 correlates with poor patient prognosis in epithelial ovarian cancer. PLoS ONE 12, e0174037 (2017).","journal-title":"PLoS ONE"},{"key":"21546_CR100","doi-asserted-by":"publisher","first-page":"e17193","DOI":"10.1371\/journal.pone.0017193","volume":"6","author":"K-Y Lin","year":"2011","unstructured":"Lin, K.-Y. et al. Overexpression of nuclear protein kinase CK2 \u03b1 catalytic subunit (CK2\u03b1) as a poor prognosticator in human colorectal cancer. PLoS ONE 6, e17193 (2011).","journal-title":"PLoS ONE"},{"key":"21546_CR101","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1158\/1078-0432.CCR-09-3031","volume":"16","author":"P Secchiero","year":"2010","unstructured":"Secchiero, P. et al. The oncogene DEK promotes leukemic cell survival and is downregulated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells. Clin. Cancer Res. 16, 1824\u20131833 (2010).","journal-title":"Clin. Cancer Res."},{"key":"21546_CR102","first-page":"4150","volume":"118","author":"DJ Christensen","year":"2011","unstructured":"Christensen, D. J. et al. SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: A predictor of aggressive disease and a new treatment target. Blood J. Am. Soc. Hematol. 118, 4150\u20134158 (2011).","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"21546_CR103","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/10428190400018398","volume":"46","author":"L Martinez-Lostao","year":"2005","unstructured":"Martinez-Lostao, L. et al. Role of the STAT1 pathway in apoptosis induced by fludarabine and JAK kinase inhibitors in B-cell chronic lymphocytic leukemia. Leuk. Lymphoma 46, 435\u2013442 (2005).","journal-title":"Leuk. Lymphoma"},{"key":"21546_CR104","doi-asserted-by":"publisher","first-page":"152048","DOI":"10.1016\/j.imbio.2020.152048","volume":"226","author":"J Schmohl","year":"2021","unstructured":"Schmohl, J. et al. Expression profiles of HMGB1 on B-CLL related leukocytes contribute to prediction of relapse. Immunobiology 226, 152048 (2021).","journal-title":"Immunobiology"},{"key":"21546_CR105","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1074\/mcp.RA117.000539","volume":"17","author":"HE Johnston","year":"2018","unstructured":"Johnston, H. E. et al. Proteomics profiling of CLL versus healthy B-cells identifies putative therapeutic targets and a subtype-independent signature of spliceosome dysregulation. Mol. Cell. Proteomics 17, 776\u2013791 (2018).","journal-title":"Mol. Cell. Proteomics"},{"key":"21546_CR106","doi-asserted-by":"publisher","first-page":"650","DOI":"10.3390\/cancers12030650","volume":"12","author":"S Roy Chowdhury","year":"2020","unstructured":"Roy Chowdhury, S. et al. Mitochondrial respiration correlates with prognostic markers in chronic lymphocytic leukemia and is normalized by ibrutinib treatment. Cancers (Basel) 12, 650 (2020).","journal-title":"Cancers (Basel)"},{"key":"21546_CR107","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/leu.2008.399","volume":"23","author":"D Rossi","year":"2009","unstructured":"Rossi, D. et al. Telomere length is an independent predictor of survival, treatment requirement and Richter\u2019s syndrome transformation in chronic lymphocytic leukemia. Leukemia 23, 1062\u20131072 (2009).","journal-title":"Leukemia"},{"key":"21546_CR108","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.2217\/fon.09.72","volume":"5","author":"C Pepper","year":"2009","unstructured":"Pepper, C., Hewamana, S., Brennan, P. & Fegan, C. NF-\u03baB as a prognostic marker and therapeutic target in chronic lymphocytic leukemia. Future Oncol. 5, 1027\u20131037 (2009).","journal-title":"Future Oncol."},{"key":"21546_CR109","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1172\/JCI23409","volume":"115","author":"BT Messmer","year":"2005","unstructured":"Messmer, B. T. et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J. Clin. Invest. 115, 755\u2013764 (2005).","journal-title":"J. Clin. Invest."},{"key":"21546_CR110","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.it.2013.07.002","volume":"34","author":"JA Burger","year":"2013","unstructured":"Burger, J. A. & Chiorazzi, N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol. 34, 592\u2013601 (2013).","journal-title":"Trends Immunol."},{"key":"21546_CR111","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11010-008-9820-7","volume":"316","author":"J D\u00f6rr","year":"2008","unstructured":"D\u00f6rr, J., Kartarius, S., G\u00f6tz, C. & Montenarh, M. Contribution of the individual subunits of protein kinase CK2 and of hPrp3p to the splicing process. Mol. Cell Biochem. 316, 187\u2013193 (2008).","journal-title":"Mol. Cell Biochem."},{"key":"21546_CR112","doi-asserted-by":"publisher","first-page":"799","DOI":"10.4049\/jimmunol.2100059","volume":"207","author":"H Wei","year":"2021","unstructured":"Wei, H. et al. Protein kinase CK2 regulates B cell development and differentiation. J. Immunol. 207, 799\u2013808 (2021).","journal-title":"J. Immunol."},{"key":"21546_CR113","doi-asserted-by":"publisher","first-page":"11375","DOI":"10.1158\/0008-5472.CAN-05-1602","volume":"65","author":"SF Eddy","year":"2005","unstructured":"Eddy, S. F. et al. Inducible IkappaB kinase\/IkappaB kinase epsilon expression is induced by CK2 and promotes aberrant nuclear factor-kappaB activation in breast cancer cells. Cancer Res. 65, 11375\u201311383 (2005).","journal-title":"Cancer Res."},{"key":"21546_CR114","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3389\/fnmol.2018.00146","volume":"11","author":"Q Zhang","year":"2018","unstructured":"Zhang, Q. et al. CK2 phosphorylating I 2PP2A\/SET mediates Tau pathology and cognitive impairment. Front. Mol. Neurosci. 11, 146 (2018).","journal-title":"Front. Mol. Neurosci."},{"key":"21546_CR115","doi-asserted-by":"publisher","first-page":"6011","DOI":"10.1128\/MCB.24.13.6011-6020.2004","volume":"24","author":"F Kappes","year":"2004","unstructured":"Kappes, F. et al. Phosphorylation by protein kinase CK2 changes the DNA binding properties of the human chromatin protein DEK. Mol. Cell Biol. 24, 6011\u20136020 (2004).","journal-title":"Mol. Cell Biol."},{"key":"21546_CR116","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/ijc.23094","volume":"122","author":"S Pluemsampant","year":"2008","unstructured":"Pluemsampant, S., Safronova, O. S., Nakahama, K. I. & Morita, I. Protein kinase CK2 is a key activator of histone deacetylase in hypoxia-associated tumors. Int. J. Cancer 122, 333\u2013341 (2008).","journal-title":"Int. J. Cancer"},{"key":"21546_CR117","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1365-2141.2010.08425.x","volume":"152","author":"SL Elliott","year":"2011","unstructured":"Elliott, S. L. et al. Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: A potential therapy for high risk B-cell chronic lymphocytic leukaemia. Br. J. Haematol. 152, 61\u201371 (2011).","journal-title":"Br. J. Haematol."},{"key":"21546_CR118","doi-asserted-by":"publisher","first-page":"35946","DOI":"10.18632\/oncotarget.9371","volume":"7","author":"N Papakonstantinou","year":"2016","unstructured":"Papakonstantinou, N. et al. The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia. Oncotarget 7, 35946 (2016).","journal-title":"Oncotarget"},{"key":"21546_CR119","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1159\/000334577","volume":"81","author":"JC Wang","year":"2011","unstructured":"Wang, J. C. et al. Histone deacetylase in chronic lymphocytic leukemia. Oncology 81, 325\u2013329 (2011).","journal-title":"Oncology"},{"key":"21546_CR120","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","volume":"23","author":"CA Lipinski","year":"1997","unstructured":"Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3\u201325 (1997).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"21546_CR121","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","volume":"1","author":"CA Lipinski","year":"2004","unstructured":"Lipinski, C. A. Lead-and drug-like compounds: The rule-of-five revolution. Drug Discov. Today Technol. 1, 337\u2013341 (2004).","journal-title":"Drug Discov. Today Technol."},{"key":"21546_CR122","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1021\/jm020017n","volume":"45","author":"DF Veber","year":"2002","unstructured":"Veber, D. F. et al. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45, 2615\u20132623 (2002).","journal-title":"J. Med. Chem."},{"key":"21546_CR123","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","volume":"138","author":"UM Zanger","year":"2013","unstructured":"Zanger, U. M. & Schwab, M. Pharmacology & Therapeutics Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 138, 103\u2013141 (2013).","journal-title":"Pharmacol. Ther."},{"key":"21546_CR124","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.3390\/molecules25061375","volume":"25","author":"X Lin","year":"2020","unstructured":"Lin, X., Li, X. & Lin, X. A review on applications of computational methods in drug screening and design. Molecules 25, 1375 (2020).","journal-title":"Molecules"},{"key":"21546_CR125","doi-asserted-by":"publisher","first-page":"113705","DOI":"10.1016\/j.ejmech.2021.113705","volume":"224","author":"VT Sabe","year":"2021","unstructured":"Sabe, V. T. et al. Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: A review. Eur. J. Med. Chem. 224, 113705 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"21546_CR126","doi-asserted-by":"publisher","first-page":"580","DOI":"10.3390\/cryst10070580","volume":"10","author":"VRA Dubach","year":"2020","unstructured":"Dubach, V. R. A. & Guskov, A. The resolution in X-ray crystallography and single-particle cryogenic electron microscopy. Crystals (Basel) 10, 580 (2020).","journal-title":"Crystals (Basel)"},{"key":"21546_CR127","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.3324\/haematol.2020.246918","volume":"106","author":"Y Zhou","year":"2021","unstructured":"Zhou, Y. et al. The multifaceted role of protein kinase CK2 in high-risk acute lymphoblastic leukemia. Haematologica 106, 1461 (2021).","journal-title":"Haematologica"},{"key":"21546_CR128","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.1016\/j.jmb.2020.01.003","volume":"432","author":"S Miller","year":"2020","unstructured":"Miller, S. & Hirota, T. Pharmacological interventions to circadian clocks and their molecular bases. J. Mol. Biol. 432, 3498\u20133514 (2020).","journal-title":"J. Mol. Biol."},{"key":"21546_CR129","doi-asserted-by":"publisher","first-page":"100272","DOI":"10.1016\/j.jics.2021.100272","volume":"98","author":"S Ghosh","year":"2021","unstructured":"Ghosh, S., Das, S., Ahmad, I. & Patel, H. In silico validation of anti-viral drugs obtained from marine sources as a potential target against SARS-CoV-2 Mpro. J. Indian Chem. Soc. 98, 100272 (2021).","journal-title":"J. Indian Chem. Soc."},{"key":"21546_CR130","doi-asserted-by":"crossref","unstructured":"Ayipo, Y. O. et al. Molecular modelling and structure-activity relationship of a natural derivative of o-hydroxybenzoate as a potent inhibitor of dual NSP3 and NSP12 of SARS-CoV-2: In silico study. J. Biomol. Struct. Dyn. 40, 1\u201319 (2022).","DOI":"10.1080\/07391102.2022.2026818"},{"key":"21546_CR131","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ijbiomac.2021.08.224","volume":"190","author":"HY Lee","year":"2021","unstructured":"Lee, H. Y. et al. Mining of a novel esterase (est3S) gene from a cow rumen metagenomic library with organosphosphorus insecticides degrading capability: Catalytic insights by site directed mutations, docking, and molecular dynamic simulations. Int. J. Biol. Macromol. 190, 441\u2013455 (2021).","journal-title":"Int. J. Biol. Macromol."},{"key":"21546_CR132","doi-asserted-by":"crossref","unstructured":"Acar \u00c7evik, U. et al. Design, synthesis, molecular modeling, DFT, ADME and biological evaluation studies of some new 1, 3, 4-oxadiazole linked benzimidazoles as anticancer agents and aromatase inhibitors. J. Biomol. Struct. Dyn. 1\u201315 (2022).","DOI":"10.1080\/07391102.2022.2025906"},{"key":"21546_CR133","doi-asserted-by":"publisher","first-page":"131124","DOI":"10.1016\/j.molstruc.2021.131124","volume":"1246","author":"F Azam","year":"2021","unstructured":"Azam, F., Eid, E. E. M. & Almutairi, A. Targeting SARS-CoV-2 main protease by teicoplanin: A mechanistic insight by docking, MM\/GBSA and molecular dynamics simulation. J Mol Struct 1246, 131124 (2021).","journal-title":"J Mol Struct"},{"key":"21546_CR134","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/1471-2164-10-365","volume":"10","author":"M Gry","year":"2009","unstructured":"Gry, M. et al. Correlations between RNA and protein expression profiles in 23 human cell lines. BMC Genomics 10, 365 (2009).","journal-title":"BMC Genomics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21546-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21546-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21546-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T09:48:59Z","timestamp":1701251339000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21546-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":134,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["21546"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-21546-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,21]]},"assertion":[{"value":"17 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17648"}}